FOXO4 Peptide Reduces Lung Scarring by Targeting Fibrosis-Driving Cells

Pulmonary fibrosis is a progressive and often fatal chronic lung disease characterized by excessive accumulation of extracellular matrix (ECM) and the uncontrolled proliferation and activation of myofibroblasts, leading to irreversible lung scarring and impaired function. Current therapeutic options are limited and often fail to halt disease progression effectively, highlighting an urgent need for novel interventions. This study addresses the critical knowledge gap in identifying specific molecular targets and therapeutic agents that can effectively suppress myofibroblast activity and ECM deposition in fibrotic lung disease.

Treatment with FOXO4 peptide significantly ameliorated the severity of pulmonary fibrosis in the bleomycin-challenged mice. Histological analysis revealed a marked reduction in fibrotic lesions and improved lung architecture in the treated group. FOXO4 peptide administration resulted in a remarkable 43% reduction in lung collagen deposition (measured by hydroxyproline content, p<0.01) and a 35% improvement in histological fibrosis scores compared to untreated fibrotic controls. Specifically, the peptide treatment led to a 2.5-fold decrease in the expression of α-SMA (alpha-smooth muscle actin), a marker of myofibroblast activation, and a 2.1-fold reduction in collagen I mRNA levels in lung tissues. Mechanistically, the study identified that FOXO4 peptide modulated key components of the ECM-receptor interaction pathway, suggesting its role in disrupting pro-fibrotic signaling.